Physician profile
Melissa Stade
NPI 1164543674
$3,462.67
in general payments reported to CMS, 2019-2025
15 companies · $824 in 2025
The $824 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.87 · 2020: $11.51 · 2021: $2,205 · 2022: $73.87 · 2023: $18.99 · 2024: $283 · 2025: $824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $693 · Food and Beverage: $433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $693.30 |
| Food and Beverage | $432.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,213.61 | 2019-2021 | |
| Davol INC. | $693.30 | 2025 | Phasix Mesh |
| Endomagnetics LTD | $153.45 | 2024 | Magseed, Magtrace |
| Smith+Nephew, INC. | $86.76 | 2024-2025 | Oasis, Grafix Pl, Stravix |
| Stryker Corporation | $59.94 | 2022 | |
| Solventum Corporation | $48.26 | 2024-2025 | Prevena, V.A.C.Ulta, V.A.C. Veraflo |
| Kerecis Limited | $48.07 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Phathom Pharmaceuticals, INC. | $39.06 | 2025 | Voquezna |
| Pfizer INC. | $35.36 | 2021-2025 | |
| Kci USA, INC. | $18.99 | 2023 | V.A.C.Instill, Activ.A.C., Promogran Prisma |
| Janssen Biotech, INC. | $16.61 | 2025 | Tremfya |
| Medline Industries LP | $13.93 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $13.83 | 2021 | |
| Covidien LP | $11.51 | 2020 | |
| Organogenesis INC. | $9.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Stade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.